Take a look through some of the notable data presentations at this year's ESMO Congress.
News|Articles|February 23, 2026
Conference Preview: Late-Breaking Abstracts at ASCO GU 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.
Advertisement
Advertisement
The late-breaking abstracts (LBAs) at this year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium offer an early look at data that may meaningfully shift clinical decision-making across urologic oncology. As the treatment landscape continues to evolve, particularly with the expansion of targeted therapies, antibody-drug conjugates, and perioperative immunotherapy strategies, this year’s LBA slate reflects a growing emphasis on biomarker-driven care and treatment intensification across disease states.
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement